MTPConnect’s CTCM program launches next funding opportunity to boost commercialisation of Australian medical devices

Banner Image

27 July 2022

The Clinical Translation and Commercialisation Medtech (CTCM) Program, a Medical Research Future Fund (MRFF) initiative delivered by MTPConnect, will open its second round in September 2022. Applications are sought from Australian small to medium-sized enterprises (SMEs) developing home-grown medical devices.

The CTCM Program will provide funding between $250,000 to $1.5 million to accelerate eligible projects delivered over a maximum 24-month period.

To be considered for funding, projects must focus on the development of a medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body.

Activities to be funded include, but are not limited to, prototype development and product testing, clinical trial activity and regulatory support.

MTPConnect Chief Executive Officer, Stuart Dignam, says this will be the final funding round of the CTCM program, providing another opportunity for local innovators to be part of Australia’s growing medical products sector.   

“We are looking to provide funding and support to projects where the device’s capability has already been validated with research and/or preclinical studies,” Mr Dignam said.

“Applicants will also be required to provide a cash co-contribution dependent on the total CTCM funding request, with additional in-kind or cash contributions above this threshold viewed favourably. 

“The CTCM program was designed uniquely to leverage a national alliance of experts in the medtech sector. We are delighted to work closely with medtech partners: Medical Technology Association of Australia (MTAA), Cicada Innovations and Medical Device Partnering Program (MDPP), as well as infrastructure partner, Therapeutic Innovation Australia (TIA), and educational partner, QUT – The BridgeTech Program.

“So, in addition to financial support, applicants will be supported throughout the 24-month period with valuable educational support, consultation and access to critical engineering, fabrication and prototyping facilities to help accelerate translation of their medical device,” Mr Dignam said.

A hybrid Information Session about applying for CTCM Round 2 will be held in Brisbane on Tuesday 23 August at 1:00pm AEST. Register now to attend in-person or virtually.

Expressions of Interests (EOI) for the second round of CTCM funding open on 9 September 2022 and will close on Friday 7 October 2022 at 4:00pm AEDT.

A sample EOI application form is available online now to provide an overview of what will be required at the time of submission. For further details on eligibility and application requirements, visit the MTPConnect website. All applications must be made through SmartyGrants.

Queries can be sent via email to